IP Bridge (IPB) – the company that operates Japan’s sovereign patent fund (SPF) – announced last week that it has signed a drug discovery deal with Kyushu University, indicating that it is aiming beyond straight monetisation activities to fulfil its originally stated objectives of facilitating open innovation and putting Japan’s vast stockpile of dormant intellectual property to work.

Want to read more?

Register to access two of our subscriber-only articles per month

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts

Already registered? Log in

What our customers are saying

One of the advantages of IAM is that it is high quality and yet still accessible and relevant to the non-specialist chief executives and senior managers who don't know what they don't know about IP. It's an important contribution to the upward IP education of senior managers.

Ian Harvey
Board member
International Intellectual Property Strategists Association (INTIPSA)


Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.

Why subscribe?